Ivax Corp. received final approval from the FDA for tizanidine HCl in 2 mg and 4 mg tablet dosages. The drug is the generic equivalent of Zanaflex, marketed by Elan Pharmaceuticals as a muscle relaxant. According to IMS Health data, U.S. sales of Zanaflex totaled $119 million for the 12-month period ended June 30.
Ivax also received final approval for brimonidine tartrate ophthalmic solution 0.2 percent, the generic equivalent of Alphagen, marketed by Allergan for the treatment of glaucoma. According to IMS data, U.S. sales of Alphagen 0.2 percent solution totaled $8 million for the same 12-month period.
COPYRIGHT 2004 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2004 Gale Group